Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PROTECTOR/FIRE-10 preoperative systemic therapy trial in resectable advanced colon cancer
2023-508076-11-00Phase 3Authorised
- Sponsor
- Charité – Universitätsmedizin Berlin
- Start
- Nov 2024
- Modality
- Small Molecules, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Irreversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of oxaliplatin, irinotecan, fluorouracil, capecitabine and folinic acid in colon cancer and rectal cancer (2 arms), sponsored by Charité – Universitätsmedizin Berlin. Primary endpoint: Disease-free survival. Planned start Nov 2024; status: authorised.
02
Drugs
oxaliplatinirinotecanfluorouracilcapecitabinefolinic acid
03
Conditions
colon cancerrectal cancer
Beyond the preview
Go deeper on 2023-508076-11-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-508076-11-00.